Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?
- 1 January 1995
- journal article
- research article
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 7 (1) , 17-28
- https://doi.org/10.3109/09540269509022972
Abstract
Rational drug development has come to psychiatry. Both the promise and the challenge that comes with this fact are great. One issue raised is whether to decide rationally to develop drugs with more than one mechanism of action (MOA) to improve efficacy and/or tolerability. As with any issue in science, thinking and planning will only take one so far. After that, the dice must be rolled and the results assessed. Undoubtedly, some drugs with dual or even more MOAs will prove to be desirable and others not. The question is which ones.Keywords
This publication has 8 references indexed in Scilit:
- Targeted pharmacotherapy in depression managementInternational Clinical Psychopharmacology, 1994
- Binding of antidepressants to human brain receptors: focus on newer generation compoundsPsychopharmacology, 1994
- The Effects of Fluoxetine on the Polysomnogram of Depressed Outpatients: A Pilot StudyNeuropsychopharmacology, 1994
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sciences, 1993
- Potential Indications for the Selective Serotonin Reuptake InhibitorsInternational Clinical Psychopharmacology, 1992
- The Future and Psychopharmacology: Potentials and NeedsPsychiatric Annals, 1990
- Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter studyJournal of Affective Disorders, 1990
- Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitorJournal of Psychopharmacology, 1987